Detection of Diverse Hepatitis C Virus (HCV)-Specific Cytotoxic T Lymphocytes in Peripheral Blood of Infected Persons by Screening for Responses to All Translated Proteins of HCV

DAVID K. H. WONG,1 DARRYL D. DUDLEY,1 PAUL B. DOHRENWEND,1 GEORG M. LAUER,1 RAYMOND T. CHUNG,2 DAVID L. THOMAS,3 AND BRUCE D. WALKER1*

Partners AIDS Research Center, Infectious Disease Division,1 and Gastrointestinal Unit,2 Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Johns Hopkins School of Medicine, Baltimore, Maryland3

Received 21 July 2000/Accepted 3 November 2000

Cytotoxic T lymphocytes (CTL) potentially play a major role in the pathogenesis of chronic viral infections because they are capable of recognizing virus-infected cells (18, 29, 37) and responding either directly, by lysis of the infected cell, or indirectly, by secreting cytokines that inhibit viral replication and/or recruit other nonspecific inflammatory cells (9, 10, 40). In acute hepatitis C virus (HCV) infection, a strong virus-specific CTL response seems to be associated with spontaneous viral clearance (6, 8, 24), whereas in chronic infection, the role of CTL is still under debate. CTL studies of HCV-infected persons have been hampered by the relatively low frequency of specific cells in the peripheral blood and by the fact that the targeted epitopes vary depending on the HLA type of the individual. The majority of studies of HCV-specific CTL in peripheral blood have been based on testing predicted epitopes, and most have focused on HLA A2-positive persons (2, 4, 8, 23, 27, 28).

In subjects with chronic HCV infection, HCV-specific CTL responses presented by A2 and non-A2 alleles have been detected from liver-derived lymphocytes that have been polyclonally expanded using a CD3-specific monoclonal antibody (19–21, 26, 39). The CTL responses defined in this manner are presumed to reflect in vivo-determined specificities. However, liver-derived lymphocytes are not easily studied. The risks and discomforts of liver biopsy make it difficult to study subjects frequently in a longitudinal fashion or to study subjects with mild or acute disease for whom liver biopsies are not clinically indicated.

Peripheral blood-derived lymphocytes are easier to obtain than liver tissue, but previous attempts to detect HCV-specific CTL activity from peripheral blood mononuclear cells (PBMC) stimulated with anti-CD3 have been unsuccessful (21). This finding is consistent with the hypothesis that HCV-specific responses are compartmentalized to the liver and are present in PBMC in much lower frequencies. Other groups have detected CTL from PBMC that had been stimulated in an antigen-specific manner using synthetic HCV peptides, but these studies have been largely limited to detection of known or predicted class I-restricted epitopes (2, 4, 12, 15, 16, 23, 28, 32, 33). CTL responses identified in this manner do not allow detection of responses restricted by many class I alleles for which epitope predictions are not available or those that are missed by the prediction algorithms. Furthermore, some HCV peptides have been reported to induce CTL responses in HCV-seronegative subjects, raising the possibility that some of these responses may be due to primary in vitro sensitization (3, 22).

An alternative approach to antigen-specific stimulation has been described for detecting virus-specific CTL (14, 25). Recombinant vaccinia virus vectors can be used to introduce antigens into B-lymphoblastoid cell lines for processing...
through the class I pathway. After inactivation of the vaccinia virus by psoralen and long-wave UV irradiation, the cells are used to stimulate PBMC. This system has the advantage of having all potential CTL epitopes presented in the context of all the autologous HLA class I alleles.

In this study, we used a vaccinia virus system to express the entire translated polyprotein of HCV-H (a type 1a strain) in autologous B-lymphoblastoid cell lines (B-LCL) and then exposed the cells to long-wave UV light (8-W solution, 9-fluorenylmethoxy carbonyl method. Peptides were 20 aa in length, overlapping adjacent peptides by 10 aa. Fine mapping was achieved using additional smaller peptides in free acid form that were synthesized on an automated peptide synthesizer (model 432A; Applied Biosystems, Inc., Foster City, Calif.). All HLA typing was performed on additional samples of venous blood by the Massachusetts General Hospital Tissue Typing Laboratory, using standard serologic techniques. Sera and plasma, as well as the remaining PBMC, were stored at −80°C. Informed consent was obtained from all subjects, and the study was approved by the Massachusetts General Hospital Internal Review Board.

Stimulation of PBMC in bulk cultures. Lymphocytes (10^6 cells) from PBMC were polyclonally expanded in an antigen-nonspecific manner with the CD3-specific monoclonal antibody 12F6 (0.1 μg/ml) and 20 × 10^6 irradiated (30 Gy) allogeneic PBMC feeder cells in 20 ml of R-10 medium. On day 3, recombinant interleukin-2 (rIL-2) was added to achieve a final concentration of 50 U/ml. Lymphocytes were also expanded in an antigen-specific manner, using a protocol modified from Lubaki et al. (25). Stimulator cells that present all potential HCV antigens in the context of the autologous HLA alleles were prepared by infecting autologous B-LCL (8 × 10^5 cells) with the vaccinia virus-HCV (vv-HCV) recombinant viruses (see below) vv1-966(H1) and vv827-3011(H2) at a multiplicity of infection of 5 to 10 h.<br>

RESULTS

HCV-specific CTL are present in PBMC of persons with chronic HCV infection. To determine if HCV-specific CTL can be detected in the peripheral blood of persons with chronic HCV infection, we initially examined a subject (P1) who had previously been shown to have a broadly directed response in the liver with five different CTL epitopes characterized (20). This subject had since completed a 5-month course of interferon therapy (he withdrew from the last month of treatment), resulting in a complete biochemical and virological response which has been sustained for over 1 year. A liver biopsy specimen, obtained prior to initiation of interferon therapy, and cryopreserved PBMC, obtained 3 months after starting interferon therapy, were available for study. Bulk stimulated cultures of PBMC expanded in an antigen-nonspecific manner with the anti-CD3 monoclonal antibody 12F6 had no evidence of HCV-specific CTL activity (Fig. 1A), which is consistent with our previous findings (19–21, 38). To increase the sensitivity of CTL detection, multiple clones were also established from PBMC by culturing at limiting dilution after stimulation with 12F6. Of the 105 clones tested, 2 lysed autologous B-LCL
targets that expressed E2/NS2 (aa 339 to 906) of HCV-1 (Fig. 1B). CTL of similar specificity were obtained from intrahepatic lymphocytes with anti-CD3 stimulation (39). These data demonstrate that CTL of the same specificity as detected in liver can be detected at a clonal level in peripheral blood, but the frequencies are below the detection limit of bulk assays.

Detection of HCV-specific CTL can be enhanced by antigen-specific stimulation. To increase the sensitivity for detecting CTL, PBMC from the same individual were stimulated with autologous cells expressing HCV proteins. This was accomplished by infecting autologous B-LCL with recombinant vv-HCV constructs, leading to the expression of the entire translated polyprotein of HCV-H, a type 1a strain. Using this method, HCV-specific CTL activity was detected in bulk PBMC cultures (Fig. 1C). This bulk-stimulated PBMC culture was also cloned at limiting dilution using anti-CD3 monoclonal antibody so that the CTL response in peripheral blood could be characterized and compared to the CTL response in the liver. Of the 120 clones tested, 32 HCV-specific clones were identified. All five CTL epitopes recognized by the liver-derived clones were also recognized by at least one of the PBMC-derived clones (Fig. 2).

To assess the ability of this method to detect CTL in PBMC, we examined seven subjects with chronic HCV infection in whom CTL had been detected from liver-derived lymphocytes and for whom cryopreserved PBMC were available (Fig. 3A). PBMC stimulated with the anti-CD3 monoclonal antibody 12F6 had a 40- to 100-fold expansion in the total number of cells after 2 weeks, as assessed by absolute cell counts (Table 1). This indicates that the cryopreserved PBMC were viable and able to proliferate. Proliferation following stimulation with autologous B-LCL infected with recombinant vv-HCV, in which one would expect preferential expansion of HCV-specific CTL, had a 0.25- to 40-fold expansion over the same period of time. Nonspecific responses, possibly reflecting T-cell responses to vaccinia virus or EBV resulting in vv-Lac-specific lysis of >20%, were observed in 8 of the 12 subjects tested. However, three of the seven subjects with intrahepatic CTL also had detectable HCV-specific PBMC CTL using this antigen-specific stimulation method to establish polyclonal cell lines (P1, P2, and P3) (Fig. 3B). These results were confirmed by the establishment of PBMC clones from these three subjects (Fig. 3B). In addition, CTL were detected in PBMC from an additional two subjects (P4 and P5) after HCV-vv stimulated PBMC were cloned and screened for CTL responses (Fig. 3B). The specificities of the PBMC-derived CTL were identical to those that had been derived from liver. Another two subjects (P8 and P9) who did not have intrahepatic CTL were also studied, and neither of these had evidence of CTL in PBMC. Of the two subjects with discordant results between liver and PBMC CTL, P6 had a vigorous intrahepatic CTL response but no evidence of CTL from the PBMC sample obtained 1 year after the liver biopsy. Unfortunately, no PBMC samples were available from the time when the liver biopsy was obtained. P7 had a low frequency of intrahepatic CTL and no evidence of CTL from a PBMC sample from the same time point.

PBMC from three HCV-seronegative subjects were also examined, but no HCV-specific CTL were detected after antigen-specific stimulation with autologous B-LCL expressing HCV-H (Fig. 3B). Two of these three subjects were
HLA B35 positive and were previously reported to have HLA B35-restricted CTL responses in PBMC after in vitro stimulation with the peptide P401 (aa 234 to 242, NASRC-WVAM) (22). Once again, HLA B35-restricted CTL clones were obtained from both subjects following stimulation with peptide P401. However, similar to previous results, these CTL only recognized cells incubated with P401, not the endogenously processed antigen when the vaccinia virus expression system was used (22 and data not shown). Together, the data suggest that antigen-specific stimulation of PBMC using recombinant HCV-vv-driven expression of HCV antigens in autologous B-LCL can be used to detect CTL responses in the majority of subjects with intrahepatic CTL responses and that these responses reflect recognition of endogenously processed antigen.

**No evidence of CTL in a cohort at high risk for HCV exposure.** A cohort of injection drug users in Baltimore has been followed for incidence and prevalence of several blood-borne pathogens. The prevalence of HCV was very high in this group, with frequent use and sharing of drug paraphernalia identified as factors for HCV seroconversion among those who were initially HCV seronegative (35). However, a subgroup remained HCV seronegative despite a history of continued high-risk behavior. This group was studied to determine if there was evidence of HCV-specific CTL that might account for their remaining HCV seronegativity. Cryopreserved PBMC from 10 subjects were obtained from this cohort, 8 who remained HCV seronegative and 2 who had developed chronic HCV infection. Assays were performed in a blinded fashion. Two of the 10 subjects had detectable CTL responses in PBMC, and upon unblinding, both were shown to be HCV seropositive (Table 2). Subject A had a CTL response to one epitope within aa 347 to 906, and subject B had CTL responses to an epitope in the E1 (aa 285 to 293) and NS2 (aa 838 to 846) proteins (Table 2 and data not shown). The remaining eight subjects were HCV seronegative and had no evidence of HCV-specific CTL responses. These data are in conflict with the hypothesis that
memory CTL generated from previous exposure were responsible for the continued HCV-seronegative status of these individuals. CTL may be present but below the limit of detection of this assay, in which case they are of lower cell viability, as cells expanded after stimulation with the anti-CD3 monoclonal antibody 12F6.

### DISCUSSION

The role of HCV-specific CTL in the pathogenesis of HCV infection is still unclear. Most studies have been conducted on chronically infected subjects, which have been the easiest to identify. HCV-specific CTL have been identified in the majority of these subjects from lymphocytes isolated from liver (26, 39). CTL have also been detected by in vitro stimulation with viral peptides. These methods are largely limited to detection of predicted epitopes and therefore do not provide a comprehensive analysis of CTL to all possible presented epitopes (2, 4, 12, 15, 17, 23, 28, 32, 33). In addition, peptide-specific approaches limit the analysis to known particular peptides and alleles. The ability to study CTL responses in HLA-diverse populations and to study responses to the entire translated polyprotein will allow a more comprehensive characterization of this response. This would be particularly advantageous for situations when liver biopsy is not feasible, such as for subjects with acute HCV infection, uninfected subjects, and studies for which frequent samples are required.

In this study, we have used vaccinia virus infection to express HCV-H antigens (type 1a strain) in autologous B-lymphoblastoid cells. These cells were then used to stimulate PBMC. The advantage of this system is that the PBMC are exposed to antigens from the entire HCV-H genome and expressed in the context of all autologous HLA alleles. Furthermore, over 75% of subjects in North America are infected with genotype 1 viruses, which would have a relatively high degree of homology with HCV-H (1). Our results indicate that the majority of persons with chronic HCV infection have circulating CTL and that these target epitopes are similar to those targeted by the intrahepatic CTL response. A potential problem with this system is that the PBMC are also exposed to vaccinia virus antigens and EBV antigens (EBV was used to establish the B-LCL). However, our results show that HCV-specific CTL clones can be established in the majority of subjects after one round of in vitro stimulation. Use of cold targets might be expected to lower background levels of lysis for the bulk expanded cells even further, as has been shown using this system for other viral infections (25). The high degree of concordance of HCV epitopes identified from liver and PBMC CTL suggests that this strategy is a reasonable alternative to liver biopsy studies for identifying CTL responses and epitopes. However, whether the T-cell receptor repertoire in the liver is fully represented in the peripheral blood and whether the frequency of CTL in blood will reflect frequencies in the liver are important issues that still need to be addressed.

Virus-specific CTL have been implicated as a possible protective mechanism in subjects with high-risk viral exposure, such as those exposed to human immunodeficiency virus (30, 31). To see if this was also true for HCV, we studied a cohort of injection drug users who reported prolonged and persistent high-risk behavior. We found no evidence of HCV-specific CTL that might be responsible for the persistent lack of HCV replication.

### TABLE 1. HCV-specific CTL can be detected in the majority of subjects with chronic HCV infection in whom CTL had previously been detected in the liver

<table>
<thead>
<tr>
<th>Status</th>
<th>Subject</th>
<th>Stimulation</th>
<th>Expansion (fold)</th>
<th>No. of clones/no. tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic HCV infection with intrahepatic CTL</td>
<td>P1 (94F)</td>
<td>HCV-H</td>
<td>36.8</td>
<td>32/120</td>
</tr>
<tr>
<td></td>
<td>P2 (91E)</td>
<td>HCV-H</td>
<td>0.3</td>
<td>3/166</td>
</tr>
<tr>
<td></td>
<td>P3 (94L)</td>
<td>HCV-H</td>
<td>8.2</td>
<td>0/175</td>
</tr>
<tr>
<td></td>
<td>P4 (93K)</td>
<td>HCV-H</td>
<td>5.0</td>
<td>0/120</td>
</tr>
<tr>
<td></td>
<td>P5 (95I)</td>
<td>HCV-H</td>
<td>5.0</td>
<td>0/120</td>
</tr>
<tr>
<td></td>
<td>P6 (93L)</td>
<td>HCV-H</td>
<td>0.2</td>
<td>0/120</td>
</tr>
<tr>
<td></td>
<td>P7 (95K)</td>
<td>HCV-H</td>
<td>0.5</td>
<td>0/120</td>
</tr>
</tbody>
</table>

### TABLE 2. HCV-specific CTL detected in subjects with chronic HCV infection but not in uninfected subjects despite the history of continued injection drug use

<table>
<thead>
<tr>
<th>Subject</th>
<th>HCV ELISA result</th>
<th>Stimulation</th>
<th>Expansion (fold)</th>
<th>Bulk assay result</th>
<th>No. of clones/no. tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>+</td>
<td>HCV-H</td>
<td>1.5</td>
<td>ND</td>
<td>5/105</td>
</tr>
<tr>
<td>B</td>
<td>+</td>
<td>HCV-H</td>
<td>30.0</td>
<td>Positive</td>
<td>8/78</td>
</tr>
<tr>
<td>C</td>
<td>–</td>
<td>HCV-H</td>
<td>3.0</td>
<td>Negative</td>
<td>0/120</td>
</tr>
<tr>
<td>D</td>
<td>–</td>
<td>HCV-H</td>
<td>5.0</td>
<td>Negative</td>
<td>0/120</td>
</tr>
<tr>
<td>E</td>
<td>–</td>
<td>HCV-H</td>
<td>0.3</td>
<td>ND</td>
<td>0/105</td>
</tr>
<tr>
<td>F</td>
<td>–</td>
<td>HCV-H</td>
<td>28.0</td>
<td>Negative</td>
<td>0/120</td>
</tr>
<tr>
<td>G</td>
<td>–</td>
<td>HCV-H</td>
<td>0.2</td>
<td>Negative</td>
<td>0/120</td>
</tr>
<tr>
<td>H</td>
<td>–</td>
<td>HCV-H</td>
<td>3.2</td>
<td>Negative</td>
<td>0/58</td>
</tr>
<tr>
<td>12970I</td>
<td>–</td>
<td>HCV-H</td>
<td>22.2</td>
<td>Negative</td>
<td>0/120</td>
</tr>
<tr>
<td>13173J</td>
<td>–</td>
<td>HCV-H</td>
<td>2.8</td>
<td>Negative</td>
<td>0/44</td>
</tr>
</tbody>
</table>

* Cryopreserved PBMC were stimulated and then tested for HCV-specific CTL activity using a standard 4-h chromium release assay. The cells were then subcloned and tested for HCV-specific CTL activity. HCV-specific CTL activity was detected in both subjects with chronic HCV infection but in none of the eight HCV-seronegative subjects who had been selected for high risk of viral exposure. ELISA, enzyme-linked immunosorbent assay. ND, not determined.
infection in these eight individuals. This did not appear to be caused by technical reasons, such as poor cell viability, as CTL were identified in the two chronically infected subjects, whose PBMC were analyzed identically. However, this is a difficult hypothesis to reject, as there is no guarantee of HCV exposure despite the history of high-risk behavior. In addition, it is also possible that CTL are present but below the detection limit. However, one can say that the levels of CTL are at least well below those seen in some persons with chronic uncontrolled HCV infection.

Estimating the magnitude of the CTL response using methods that require in vitro stimulation is potentially problematic since the measurements reflect the antigen-specific cells that have survived the incubation period rather than the magnitude of the immune response at the time the sample of PBMC was obtained. Newer technologies, such as Ellispot detection of cytokine secretion in response to specific antigen (24) and the use of tetramer complexes of HLA class I and viral peptide (11), have an advantage in that they do not require in vitro stimulation and can give an estimate of the frequency of antigen-specific CD8 cells within the population of PBMC. However, both techniques require initial identification of the relevant CTL epitopes and do not test the ability of CD8 cells to mediate cell lysis. To date, we have identified 39 different CTL epitopes restricted by 17 different HLA class I alleles in the HCV genome (19–21, 39). The technique reported here provides a means of identifying CTL epitopes without the need for selecting epitopes for screening or for a liver biopsy. It also allows assessment of the lytic potential of CTL responses. Together, these techniques provide the means to investigate the role that CTL play in subjects for whom liver biopsies cannot be obtained routinely.

In summary, we report the frequent detection of HCV-specific CTL in PBMC in persons with chronic HCV infection. In these subjects, the identified epitopes have a high degree of correlation with the epitopes identified from liver-derived CTL. These data indicate that CTL circulate in peripheral blood in persons with chronic HCV infection, and this method provides a means to assess CTL without the need for liver biopsy.

REFERENCES

VOL. 75, 2001 HCV-SPECIFIC CTL IN PERIPHERAL BLOOD 1235

HCV-SPECIFIC CTL IN PERIPHERAL BLOOD


